Biopharma IPO mania continues.
At least three biopharmaceutical companies with hedge fund investors are planning to go public this week, two of which count Viking Global Investors as a significant investor.
Many investors — and the financial media — are fixated on the initial public offerings (IPOs) of the so-called unicorn technology companies, most recently Slack Technologies.
